SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ariella who wrote (444)2/3/1999 1:30:00 AM
From: Rick Strange  Read Replies (2) of 1386
 
Ariella,
Since I've been involved with both companies, I'll take a shot. Sepracor has done very well with their ICE (improved chemical entity) technology. They take a chemical compound (read blockbuster drug) and tinker with the molecular chain to either enhance performance or eliminate side effects. Sometimes it's a racemic (sp) or a single isomer version that does the trick, like Allegra to replace Seldane or the new and improved version of Claritin and Prozac. In each of these examples they have cut deals for up front payments and royalty payments with the firms that have these blockbuster drugs. Eli Lilly for example will be able to extend patent protection another decade and offer a new and improved version of its multi billion dollar drug Prozac.

On a small scale PARS has done this with Lotemax by eliminating IOP usually associated with steroids. The problem here is that are no blockbuster steroids for eye use. Ditto HU211, PARS has eliminated the high associated with marajuana but there are no blockbuster marajuana based drugs approved by the FDA.

I get the impression that you are begging the question: "shouldn't we use this technology to create new and improved versions of established blockbuster drugs rather than exploring what might prove to be a undeveloped wilderness."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News